Carbimazole — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Cat	PO	Initial: 1.25-2.5 mg/cat q12h; Maintenance: 2.5-5 mg/cat q12h (up to 10 mg q12h if needed)	q12h (every 12 hours)	Duration: Long-term (lifelong) therapy; adjust based on T4 levels Notes: Start with low dose and titrate upward every 2-3 weeks based on serum T4 levels. Administer with food to reduce GI upset.
Dog	PO	5-10 mg/kg q8-12h (for thyroid carcinoma)	q8-12h	Duration: Long-term; adjust based on thyroid hormone levels Notes: Use cautiously; dogs are more sensitive to adverse effects. Monitor CBC and liver enzymes.

Clinical Indications & Species Uses

General Indications

Medical management of hyperthyroidism, particularly in cats

Dog (Canine)

Hyperthyroidism (rare, but used for thyroid carcinoma)
Thyroid hormone suppression in cases of thyroid storm

Cat (Feline)

Hyperthyroidism (feline hyperthyroidism) – first-line medical management

Pharmacology & Mechanism of Action

Drug Class: Antithyroid Agent | Pharmacological Group: Thioamide derivatives

Mechanism of Action: Carbimazole is a prodrug that is rapidly converted to methimazole (the active form) in the body. Methimazole inhibits thyroid peroxidase, the enzyme responsible for the iodination of tyrosine residues in thyroglobulin, thereby blocking the synthesis of thyroid hormones (T3 and T4). It does not affect existing thyroid hormone stores or the release of preformed hormones, so clinical effects are delayed until hormone stores are depleted. It also has mild immunosuppressive properties.

Pharmacodynamics: Carbimazole reduces the production of thyroid hormones, leading to a gradual decrease in circulating T3 and T4 levels. The onset of clinical improvement is typically seen within 1-2 weeks, with maximal effect at 3-4 weeks. It does not affect the thyroid gland's ability to take up iodine, so it does not interfere with thyroid imaging. In cats, it effectively controls hyperthyroidism, improving clinical signs such as weight loss, polyphagia, and tachycardia.

⚡ Pharmacokinetics Summary

Absorption: Carbimazole is well absorbed after oral administration. It is rapidly converted to methimazole in the gastrointestinal tract and liver. Peak plasma concentrations of methimazole occur within 1-2 hours after oral dosing.

Distribution: Methimazole is widely distributed throughout the body, including into the thyroid gland. It crosses the placenta and is distributed into milk. Protein binding is minimal (approximately 10-20%).

Metabolism: Carbimazole is rapidly hydrolyzed to methimazole. Methimazole is further metabolized in the liver, primarily by glucuronidation and sulfation.

Excretion: Methimazole and its metabolites are excreted primarily in the urine. In cats, the elimination half-life of methimazole is approximately 4-6 hours, but the pharmacodynamic effect lasts longer due to accumulation in the thyroid gland.

Half-Life: Cats: 4-6 hours (methimazole); Dogs: 4-8 hours (methimazole); Humans: 5-6 hours (methimazole)

Bioavailability: Oral bioavailability is high (approximately 80-90%) in cats and dogs.

Protein Binding: Minimal (10-20%)

Available Formulations & Strengths

Oral Tablet 1.25 mg, 2.5 mg, 5 mg, 10 mg, 20 mg (PO)

Oral Solution (compounded) Various (e.g., 5 mg/mL) (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to carbimazole or methimazole
Pregnancy (especially first trimester) – risk of fetal goiter and teratogenic effects
Lactation (excreted in milk; may cause neonatal hypothyroidism)
Pre-existing severe hepatic disease or bone marrow suppression
Concurrent use with other drugs that cause agranulocytosis

Warnings & Clinical Precautions:

Monitor for signs of bone marrow suppression (e.g., fever, sore throat, lethargy) – perform CBC at baseline and periodically
Hepatotoxicity has been reported; monitor liver enzymes
May cause immune-mediated reactions (e.g., thrombocytopenia, hemolytic anemia)
Use with caution in animals with renal disease; may alter renal function
In cats, chronic use may lead to renal decompensation; monitor renal parameters
Discontinue if severe adverse effects occur (e.g., vomiting, diarrhea, jaundice, bleeding)
Do not use in animals with known coagulopathies
May cause taste disturbances in humans handling the drug; wear gloves when administering

Adverse Effects & Reactions

Common:

Vomiting
Anorexia
Lethargy
Diarrhea
Facial pruritus (especially in cats)
Excoriation of the face/neck

Serious / Severe:

Bone marrow suppression (agranulocytosis, thrombocytopenia, leukopenia)
Hepatotoxicity (elevated liver enzymes, jaundice)
Immune-mediated hemolytic anemia
Thrombocytopenia
Renal dysfunction (especially in cats with pre-existing renal disease)

Rare:

Cutaneous drug eruptions
Lupus-like syndrome
Hypoprothrombinemia
Neuropathies
Myasthenia gravis-like syndrome

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Beta-blockers (e.g., propranolol)	May reduce metabolism of beta-blockers; additive bradycardia	Moderate
Digoxin	May increase digoxin levels; monitor for toxicity	Moderate
Warfarin and other anticoagulants	May enhance anticoagulant effect; monitor coagulation parameters	High
Theophylline	May increase theophylline clearance; adjust dose	Mild
Iodine-containing compounds	May reduce antithyroid effect; avoid concurrent use	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Vomiting
Diarrhea
Anorexia
Lethargy
Bone marrow suppression (agranulocytosis, pancytopenia)
Hepatotoxicity
Hypothyroidism (with chronic overdose)

Emergency Treatment Protocol: Induce emesis if recent ingestion and animal is stable. Administer activated charcoal to reduce absorption. Provide symptomatic and supportive care (IV fluids, antiemetics). Monitor CBC, liver enzymes, and thyroid hormone levels. For severe bone marrow suppression, consider colony-stimulating factors and antibiotics. There is no specific antidote.

Food Animal Withdrawal Times

Not approved for use in food animals; withdrawal times not established. Do not use in animals intended for food.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C)

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in a tightly closed container. Compounded solutions should be stored per compounding pharmacy instructions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use in some countries (e.g., UK).

Extra-Label (Off-Label) Use: In the US, carbimazole is not FDA-approved for veterinary use; however, it is legally used in cats under the Animal Medicinal Drug Use Clarification Act (AMDUCA) with a valid veterinarian-client-patient relationship. Extra-label use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Carbimazole is a prodrug of methimazole and is commonly used in Europe and other regions for feline hyperthyroidism. It is often preferred over methimazole because it is less bitter and may cause fewer gastrointestinal side effects. However, it is not FDA-approved in the US, so methimazole is more commonly used. Dosing should be individualized based on serum T4 levels, and regular monitoring (CBC, biochemistry, T4) is essential. In cats, renal function should be assessed before and during therapy, as hyperthyroidism can mask underlying chronic kidney disease. If renal decompensation occurs, consider alternative treatments such as radioactive iodine or thyroidectomy. Owners should be advised to wear gloves when handling the drug to avoid skin exposure. Clinical improvement is usually seen within 1-2 weeks, but full effect may take 3-4 weeks. If surgery is planned, carbimazole can be used to stabilize the patient preoperatively.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)